On October 17, 2019, the final symposium of the Major New Drug Creation Project "Phase I/II Clinical Research of CHA for Injection, a First-Created Class 1 New Drug" was held at the Institute of Materia Medica, Chinese Academy of Medical Sciences. The symposium was presided over by Zhang Jie, General Manager of Sichuan Jiuzhang Biotechnology Co., Ltd. Jiang Jiandong, Director of the Institute of Materia Medica, delivered a welcome speech, and Hu Jinfeng, Director of the Scientific Research Department, introduced the participants.

The participating units and teams of the project respectively reported on the research progress and achievements. Mr. Huang Wang from Sichuan Jiuzhang Biotech introduced the research progress of the quality control and standard establishment of CHA for injection, as well as the situation of domestic and international patent applications and authorizations. Director Li Wenbin of Beijing Tiantan Hospital introduced the results of Phase I and Phase II clinical studies on the treatment of glioma with CHA for injection. On behalf of Vice President Shen Lin, Director Gong Jifang of Beijing Cancer Hospital introduced the results of another completed Phase I clinical study on the treatment of tumors with CHA for injection. Director Jiang Jiandong of the Institute of Materia Medica introduced the new mechanism of action of CHA in inhibiting tumors through differentiation. Ji Ming, on behalf of Researcher Chen Xiaoguang, introduced the research progress of the immune mechanism of action of CHA against tumors and biomarkers. Researcher Zhang Jinlan introduced the research progress of the metabolism of CHA.

The project research progressed smoothly, and the assessment indicators were well completed. Both the anti-tumor clinical trials and the research on the mechanism of action of CHA for injection have achieved phased progress. Subsequently, the participants held a heated discussion and put forward valuable opinions and suggestions to promote the further in-depth research of the project, which will strongly promote the in-depth development of various studies of the project.